Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Silas Salano

Podiatrist, Primary Podiatric Medicine Arlington, TX Doctor of Podiatric Medicine

NPI 1598004061 CMS profile 863635

1108 W Pioneer Pkwy Ste 200, Arlington, TX 76013

Open in the dashboard

General payments

$6,444

117 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Silas Salano of Arlington, TX is reported in the CMS Open Payments database as having received $6,444 across 117 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Podiatrist, Primary Podiatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,690 14
2024 General $607 26
2023 General $670 24
2022 General $1,616 21
2021 General $337 17
2020 General $114 6
2019 General $1,410 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Silas Salano
  • Podiatrist, Primary Podiatric Medicine median
  • Middle half of Podiatrist, Primary Podiatric Medicine
  • National median

In program year 2025, general payments to Silas Salano were reported at $1,690. Among 368 Podiatrist, Primary Podiatric Medicine profiles paid that year, the median was $232 and the middle half received between $88 and $586.

Show as a table
Year Silas Salano Podiatrist, Primary Podiatric Medicine median Middle half National median
2019 $1,410 $166 $51–$513 $163
2020 $114 $108 $33–$249 $114
2021 $337 $147 $52–$377 $132
2022 $1,616 $188 $66–$551 $149
2023 $670 $195 $70–$509 $160
2024 $607 $209 $59–$508 $164
2025 $1,690 $232 $88–$586 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pylant Medical $2,459 4 payments
  2. Vilex in Tennessee, Inc. $1,312 5 payments
  3. Smith+Nephew, Inc. $381 17 payments
  4. AbbVie, Inc. $253 13 payments
  5. Nevro Corp. $238 16 payments
  6. Amgen Inc. $210 5 payments
  7. Horizon Therapeutics plc $201 5 payments
  8. Organogenesis Inc. $196 5 payments
  9. Stryker Corporation $192 7 payments
  10. Treace Medical Concepts, Inc. $127 1 payment
  11. Other $875 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,813 109 payments
  2. Education $2,315 2 payments
  3. Travel and Lodging $1,316 6 payments
Products named General payments · program years 2019–2025
  1. REDEMPTION $1,312 5 payments
  2. Senza $238 16 payments
  3. REGRANEX $219 9 payments
  4. KRYSTEXXA Inflammation/Rare Disease $210 5 payments
  5. DALVANCE $202 11 payments
  6. KRYSTEXXA Krystexxa $201 5 payments
  7. Santyl $195 8 payments
  8. TEFLARO $177 10 payments
  9. Lapiplasty System $127 1 payment
  10. MAGNETOS $124 1 payment
  11. Other $1,595 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

336

Median for Podiatry: 160

Drug cost

$22,487

Median for Podiatry: $2,368

Branded share of claims

22.9%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jublia Efinaconazole Brand 14 $17,091
Ciclopirox Generic 39 $1,147
Ammonium Lactate Generic 36 $996
Diclofenac Sodium Generic 33 $761
Doxycycline Hyclate Generic 60 $688
Ketoconazole Generic 14 $482
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 33 $470
Gabapentin Generic 25 $333
Terbinafine Hcl Generic 17 $254
Ibuprofen Generic 35 $112

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$211,175

Medicare's payments for the services billed

Medicare patients

365

Average age 78

Services billed

1,410

216 women, 149 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Diabetes 47%
Chronic kidney disease 42%
Ischemic heart disease 35%
Heart failure 34%
Depression 29%
Alzheimer's or dementia 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
  • Amgen Inc. $70
$70 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

117 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Primary Podiatric Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record